Gilead Wins Approval for a Single HIV Tablet Aimed at Patients Taking Handfuls of Pills Each Day
|
FDA approved Bixlenvo, a once-daily tablet combining
bictegravir and lenacapavir for virologically suppressed adults on complex HIV
regimens. |
Updates & Legacy — Stigmabase is a Canadian Non-Governmental & Nonprofit Initiative. Our mission is to inform about stigma around the world and make the data collected accessible for researchers. Stigmabase is very attentive to misinformation and lists only reliable sources. — The marginalization of individuals or categories of individuals is a too common phenomenon. Millions of people are facing this problem around the world and many complex factors are involved.